Within the GlobalData Pharma Intelligence Center, there are profiles of many drug candidates that focus on the prevention and treatment of colorectal cancer.
These candidates span across all stages of clinical development, with the majority being in preclinical and phase I. The figure below shows that 68% of the colorectal cancer drug candidates are in preclinical and phase I, with 45% in preclinical and 23% in phase I.
Further analysis shows that there are more drug candidates currently in the discovery and investigational new drug (IND)/clinical trial application (CTA) filed phases than in phase III. This shows that there are many more upcoming opportunities for the development of colorectal cancer products through all clinical stages.
If you would like to access to GlobalData’s Pharma Intelligence Center for more information about the colorectal cancer pipeline, or any of the other indications covered within the database, please contact a GlobalData sales representative to gain access.
For more insight and data, visit the GlobalData Report Store – Drug Development Technology is part of GlobalData Plc.
